Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312489 | 0.86 | HCAR2 (0.64) | HCAR2HDAC1HDAC8CYP1A2 | |
| SCHEMBL4548309 | 0.81 | HCAR2 (0.98) | HCAR2 | |
| SCHEMBL4548310 | 0.80 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL12808568 | 0.75 | HCAR2 (0.60) | HCAR2HDAC1HDAC8 | |
| SCHEMBL10362477 | 0.71 | HDAC1 (0.77) | HCAR2HDAC1HDAC8CYP1A2 | |
| SCHEMBL10312490 | 0.70 | HCAR2 (0.53) | HCAR2HDAC1 | |
| SCHEMBL6172461 | 0.70 | HDAC1 (0.57) | HCAR2HDAC1HDAC8CYP1A2 | |
| SCHEMBL13781545 | 0.69 | HCAR2 (0.63) | HCAR2HDAC1HDAC8CYP1A2 | |
| SCHEMBL4548311 | 0.69 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL6169879 | 0.69 | ALDH1A1 (0.60) | HCAR2HDAC1HDAC8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885HDAC1 1331/4885HDAC8 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.